Fri. Dec 13th, 2019

Kadmon biopharma shares rise on interim trial results

1 min read

Shares of Kadmon Holdings

KDMN, +11.54%

are up about 10% after the New York-based biopharmaceutical company said its treatment for certain patients with chronic graft-versus-host disease met the primary endpoint in a trial. Chronic graft-versus-host disease is a rare condition that can occur after a transplant. Kadmon said it expects to file the experimental therapy with the U.S. Food and Drug Administration next year. Its stock is up 58.65% year-to-date, while the S&P 500

SPX, +0.47%

has gained 23%.

Go to Source
Author: